NCT07227311 2025-11-12A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)GlaxoSmithKlinePhase 2 Not yet recruiting200 enrolled